Phase II Trial for Gilead’s IPF Therapy Simtuzumab Terminated After DMC Recommendation
Gilead Sciences, Inc. recently announced in a press release that it is stopping its RAINIER Phase II clinical trial testing the investigational monoclonal antibody simtuzumab in patients with idiopathic pulmonary fibrosis (IPF), noting that the experimental therapy did not demonstrate efficacy in treating the disease. Simtuzumab is a humanized monoclonal…